Le Lézard
Classified in: Health, Science and technology
Subject: Stock Sale/Buyback

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)


Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on April 30, 2024.

One individual was hired by Adicet in April 2024 and granted new hire non-qualified stock options to purchase 7,800 shares of Adicet's common stock with an exercise price of $1.49 per share, the closing price of Adicet's common stock as reported by Nasdaq on April 30, 2024. One-fourth of the shares underlying the employee's option will vest on the one-year anniversary of the recipient's start date and thereafter the remaining three-fourths of the shares underlying the employee's option will vest in thirty-six substantially equal monthly installments, such that the shares underlying the option granted to the employee will be fully vested on the fourth anniversary of the recipient's start date, subject to the employee's continued employment with Adicet on such vesting dates.

The above-described award was granted outside of Adicet's stockholder-approved equity incentive plans pursuant to Adicet's 2022 Inducement Plan (the Inducement Plan), which was adopted by the board of directors in January 2022 and subsequently amended in January 2023. The award was authorized by the compensation committee of the board of directors, which is comprised solely of independent directors, as a material inducement to the employee entering into employment with Adicet in accordance with Nasdaq Listing Rule 5635(c)(4).

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of "off-the-shelf" gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.


These press releases may also interest you

at 11:30
Wayspring, a value-based care entity focused on substance use disorder (SUD) populations, today announced a capital raise led by CVS Health Ventures. The investment recognizes Wayspring's impactful approach to managing populations with SUD,...

at 11:28
HealthCentral Corp. today announced a rebranding of its premier platform for oncologists, OBR Oncology, as Oncology News Central, reflecting the site's position as an essential hub for information and insights across the oncology landscape. ...

at 11:15
Genmab A/S announced today that it has completed its acquisition of ProfoundBio, Inc., a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADC)s and ADC technologies for the treatment of cancers in an all-cash...

at 11:08
Glooko, Inc., a global integrated digital health company connecting patients, providers, biopharma and medical partners, proudly announces the appointments of Dr. David Pass and Adam Hameed as Presidents of Life Sciences and Connected Care,...

at 11:01
According to a new market research report titled, 'IVD Quality Control Market Size, Share, Forecast & Trends Analysis by Offering (Product [Serum, Blood], Data Management, Service) Technology (Biochemistry, Molecular, Immunoassay) Application...

at 11:01
Sunburns can be painful and damaging to your skin, while also increasing your risk of skin cancer, the most common cancer in the United States and one of the most preventable. A new survey by the American Academy of Dermatology shows that one in...



News published on and distributed by: